natgillin/translations-raw huggingface dataset:
Macrogol 15 hydroxystearate Glycerol (E422) Triglycerides medium-chain
Macrogol 15 hydroxystearate Glycerol (E422)
Macugen 0,3 mg инжекционен разтвор
Macugen 0.3 mg solution for injection
Macugen 0,3 mg инжекционен разтвор пегаптаниб
Macugen 0.3 mg solution for injection pegaptanib
Macugen 0,3 mg инжекция пегаптаниб
Macugen 0.3 mg injection pegaptanib
Macugen е показан за лечение на неоваскуларна (влажна) възрастовообусловена дегенерация на макулата (ВДМ) при възрастни (вж. точка 5.1).
Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) in adults (see section 5.1).
Macugen е разтвор, който се инжектира в окото.
Macugen is a solution which is injected into the eye.
Macugen има незначително влияние върху способността за шофиране и работа с машини поради вероятност за временно замъгляване на зрението след приложение на Macugen чрез интравитреална инжекция.
Macugen has a minor influence on the ability to drive and use machines due to the possible temporary visual blurring after administration of Macugen by intravitreal injection.
Macugen не трябва да се прилага при деца и юноши под 18 години.
Macugen should not be used in children and adolescents under 18 years old.
Macugen трябва да бъде проверен визуално за видими частици и промяна в цвета преди приложение (вж. точка 6.6).
Macugen should be inspected visually for particulate matter and discoloration prior to administration (see section 6.6).
Madrid Испания
Madrid Spain
Magnesium stearate Aspartame Glycerol
Aspartame Glycerol Soya-bean oil
Magnum Veterinaaria AS
Magnum Veterinaaria AS Vae 16
Magnum Veterinārija SIA Ulbrokas iela 23, Rīga, LV-1021, Tel: +371 671 60091
Magnum Veterinārija SIA Ulbrokas iela 23, Rīga, LV-1021 Tel: +371 671 60091
Magny-Vernois 70200 Lure FRANKRIG‌‌‌
Magny-Vernois 70200 Lure FRANCE
Magtarm- kanalen
Investigations Coombs
Magyarország
France
Magyarország
Hrvatska
Magyarország
Italia
Magyarország
Latvija
Magyarország
Luxembourg/Luxemburg
Magyarország
Magyarorszag
Magyarország
Malta
Magyarország
Norge
Magyarország
Polska
Magyarország
Česká republika
Magyarország
Ελλάδα
Magyarország Grünenthal GmbH Tel: + 49 241 569-0
Magyarország Grünenthal GmbH Tel.: + 49 241 569-0
Magyarország sanofi-aventis zrt., Magyarország Tel: +36 1 505 0050
Magyarország sanofi-aventis zrt., Magyarország Tel.: +36 1 505 0050
Magyarorszбg Takeda Pharma Kft.
Luxembourg/Luxemburg
MaHRб (95% CI)
MaHRb
Majhno površino kože izpostavite sončni svetlobi za 10 minut.
Expose a small area of skin to sunlight for 10 minutes.
Majhno število belih krvnih celic, kar poveča nevarnost hude lokalne okužbe (npr. oralne, pljučne ali urinske) ali okužbe krvi
Low white blood cell count leading to increased risk of severe local (e.g.,oral, lung, urine) or blood infections
Majhno število podatkov, ki je na voljo, kaže, da je treba pri zdravljenju bolnikov z zmerno ledvično okvaro odmerek zmanjšati.
Limited data indicate that the dose should be reduced in patients with moderate renal impairment.
Majhno število podatkov, ki so na voljo, kaže, da je treba pri zdravljenju bolnikov z zmerno ledvično okvaro odmerek zmanjšati.
Limited data indicate that the dose should be reduced in patients with moderate renal impairment.
mají být sledovány nežádoucí
be monitored for tenofovir
Mají být zváženy alternativní (nehormonální) formy antikoncepce (viz bod 4.6).
Alternative forms of contraception (non-hormonal) should be considered (see section 4.6).
Makrogol 400
Macrogol 400
Maksa ja sapiteede häired
Hepatobiliary disorders
Maksa kõrvaltoimed
Hepatic adverse reactions
Maksafunktsiooni peab hoolikalt jälgima mikafungiini ravi ajal.
Liver function should be carefully monitored during micafungin treatment.
Maksakahjustusega patsiendid
Patients with hepatic impairment
Maksakahjustusega patsiendid: Mõõduka maksakahjustusega (Child-Pugh skoor 7 - 9) patsientidel (n=8) tehtud uuringus ei erinenud mikafungiini farmakokineetika oluliselt ravimi farmakokineetikast tervetel uuritavatel (n=8).
Patients with hepatic impairment: In a study performed in patients with moderate hepatic impairment (Child-Pugh score 7-9), (n=8), the pharmacokinetics of micafungin did not significantly differ from those in healthy subjects (n=8).
Makulopapulösa
Rash maculo
Malignomi
Malignancies
Mallinckrodt Deutschland GmbH Josef-Dietzgen-Str.
Mallinckrodt Deutschland GmbH Josef-Dietzgen-Str.1
Malo verjetno je, da bi zdravilo Klopidogrel Teva Pharma B.V. vplivalo na vašo sposobnost upravljanja vozil in strojev.
Clopidogrel Teva Pharma B.V. is unlikely to affect your ability to drive or operate machinery.
Malta
Deutschland
Malta
Eesti
Malta
España
Malta
France
Malta
Hrvatska
Malta
Ireland
Malta
Magyarország
Malta
Nederland
Malta
Norge
Malta
Polska
Malta
Portugal
Malta
Κύπρος
Malta (see United Kingdom)
Malta (see United Kingdom )
Malta GlaxoSmithKline Malta Tel: + 356 21 238131
Malta GlaxoSmithKline Malta Tel: + 356 21 225736
Malta GlaxoSmithKline Malta Tel: + 356 21 238131
Tel: + 356 21 238131
Malátnost
Malaise
Man har rapporterat mitokondriell dysfunktion hos hiv-negativa spädbarn som exponerats för nukleosidanaloger in utero och/eller postnatalt; dessa har främst avsett behandling med regimer innehållande zidovudin.
There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine.
manija
mania
manija (agitacija, vznesenost ali prevelika vznemirjenost)*, delirij (zmanjšano zavedanje, zmedenost, izguba občutka za resničnost)*.
Mania (agitation, feeling elated or over excited)
Manija in delirij
Mania and delirium
manitol
Mannitol
manitol (E421) klorovodikova kislina (za uravnavanje pH) natrijev hidroksid (za uravnavanje pH)
Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment)
manitol natrijev citrat voda za injekcije
Water for injections
Mannheimia haemolitica (n=50)
Mannheimia haemolytica (n=50)
Mannide mono oleate (Arlacel A) 46 l
Mannide mono oleate (Arlacel A) 46 l,
Manustamis- ja jälgimisjuhis
Administration and monitoring guide
manustamiskoha reaktsioonid
pyrexia, rigors
Manustamisviis
Method of administration
MANUSTAMISVIIS JA – TEE
METHOD AND ROUTE(S) OF ADMINISTRATION
MAO-инхибитори хинолонови антибиотици пробенецид
MAO-inhibitors quinolone antibiotics probenecid miconazole
Maravirok
Maraviroc
Maravirok je substrátem pro CYP3A a jeho plazmatická koncentrace se při souběžném podávání se silnými inhibitory CYP3A zvyšuje.
Maraviroc is a substrate of CYP3A and its plasma concentration increases when co- administered with potent CYP3A inhibitors.
Marixino 10 mg филмирани таблетки мемантин хидрохлорид
Marixino 10 mg film-coated tablets Memantine hydrochloride
Marixino 20 mg филмирани таблетки мемантин хидрохлорид
Marixino 20 mg film-coated tablets Memantine hydrochloride
Marixino е лекарство, което се използва за лечение на пациенти с умерено до тежко изразена болест на Алцхаймер, вид деменция (мозъчно нарушение), която постепенно засяга паметта, интелектуалните способности и поведението.
Marixino is a medicine used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Marixino е „генерично лекарство“.
Marixino is a ‘generic medicine’.
Marixino не се препоръчва при деца и юноши на възраст под 18 години.
Marixino is not recommended for children and adolescents under the age of 18 years.
Marixino принадлежи към група лекарства, известна като лекарства против деменция.
Marixino belongs to a group of medicines known as anti-dementia medicines.
Marixino се използва за лечение на пациенти с умерена до тежка форма на болестта на Алцхаймер.
Marixino is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Marixino трябва да се приема веднъж дневно и трябва да се приема по едно и също време всеки ден.
Marixino should be administered once a day and should be taken at the same time every day.
MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE)
MARKETING AUTHORISATION NUMBER(S)
MARKEDSFØRINGSTILLADELSENS NUMMER (NUMRE)
The NETHERLANDS
Marketing authorisation suspended
Marketing auhorisation suspended
Markörrest
Marker residue
Maropitant (som maropitantcitratmonohydrat) 10 mg
Maropitant (as maropitant citrate monohydrate) 10 mg .
Maropitant har hög bindningsgrad till plasmaproteiner och kan konkurrera med andra, starkt bundna läkemedel.
Maropitant is highly bound to plasma proteins and may compete with other highly bound drugs.
Maropitant har hög bindningsgrad till plasmaproteiner och kan konkurrera med andra, starkt bundna läkemedel.
Maropitant is highly bound to plasma proteins and may compete with other highly bound medicines.
Maropitant metaboliseras i levern och skall därför användas med försiktighet hos hundar med leversjukdom.
Maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease.
Maropitant metaboliseras via cytokrom P450 (CYP) i levern.
Maropitant undergoes cytochrome P450 (CYP) metabolism in the liver.
Maropitant omvandlas i levern och ska därför användas med försiktighet hos hundar och katter med leversjukdom.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease.
Maropitant omvandlas i levern och ska därför användas med försiktighet hos patienter med leversjukdom.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs with liver disease.
Maropitant visar linjär kinetik när det administreras subkutant inom dosområdet 0,25 - 3 mg/kg.
Maropitant displays linear kinetics when administered subcutaneously within the 0.25–3 mg/kg dose range.
Maropitant visar linjär kinetik när det administreras subkutant inom dosområdet 0,5-2 mg/kg.
Maropitant displays linear kinetics when administered subcutaneously within the 0.5–2 mg/kg dose range.
Maropitant är effektivt mot kräkning.
Maropitant is effective against vomiting.
Maropitant är en neurokinin 1 (NK1) receptorantagonist, som verkar genom att hämma bindningen av substansen P, en neuropeptid i takykininfamiljen.
Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family.
Maropitant är en potent och selektiv neurokinin (NK-1) receptorantagonist, som verkar genom att hämma bindningen av substans P, en neuropeptid i takykininfamiljen, i centrala nervsystemet.
Maropitant is a potent and selective neurokinin (NK-1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family, in the CNS.
Maropitant är en potent och selektiv neurokinin (NK-1) receptorantagonist, som verkar genom att hämma bindningen av substansen P, en neuropeptid i takykininfamiljen, i centrala nervsystemet.
Maropitant is a potent and selective neurokinin (NK-1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family, in the CNS.
Maropitant är icke-sedativt och skall inte användas som lugnande medel vid åksjuka.
Maropitant is non-sedative and should not be used as a sedative in motion sickness.
Maropitants antiemetiska effekt mot centrala och perifera emetika har visats i experimentella studier, inkluderande apomorfin, cisplatin och ipekaksirap (hundar) och xylazin (katter).
The anti-emetic efficacy of maropitant against central and peripheral emetics was demonstrated in experimental studies including apomorphine, cisplatin and syrup of ipecac (dogs) and xylazine (cats).
Maropitants biotillgänglighet efter subkutan administrering hos hundar var 90,7 %.
The bioavailability of maropitant after subcutaneous administration in dogs was 90.7%.
Maropitants biotillgänglighet efter subkutan administrering hos katter var 91,3 %.
The bioavailability of maropitant after subcutaneous administration in cats was 91.3%.
Maropitants farmakokinetiska profil vid administrering som en oral engångsdos av 2 mg/kg kroppsvikt till hundar kännetecknades av en maximal koncentration (Cmax) i plasma av cirka 81 ng/ml, vilket uppnåddes inom 1,9 timmar efter doseringen (Tmax).
The pharmacokinetic profile of maropitant when administered as a single oral dose of 2 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 81 ng/ml; this was achieved within 1.9 hours post-dosing (Tmax).
Maropitants farmakokinetiska profil vid administrering som en subkutan engångsdos av 1 mg/kg kroppsvikt till hundar kännetecknades av en maximal koncentration (Cmax) i plasma av cirka 92 ng/ml, vilket uppnåddes inom 0,75 timmar efter doseringen (Tmax).
The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 92 ng/ml; this was achieved within 0.75 hours post-dosing (Tmax).
Maropitants farmakokinetiska profil vid administrering som en subkutan engångsdos av 1 mg/kg kroppsvikt till katter kännetecknades av en maximal koncentration (Cmax) i plasma av cirka 165 ng/ml, vilket uppnåddes inom i genomsnitt 0,32 timmar (19 minuter) efter doseringen (Tmax).
The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to cats was characterised by a maximum concentration (Cmax) in plasma of approximately 165 ng/ml; this was achieved on average 0.32 hours (19 min) post-dosing (Tmax).
Maropitants plasmaproteinbindning hos hundar är mer än 99 %.
Plasma protein binding of maropitant in dogs is more than 99%.
Maropitants plasmaproteinbindning hos katter uppskattas till 99,1 %.
Plasma protein binding of maropitant in cats was estimated to be 99.1%.
Martin Linges vei 25, N-1367 Snarøya Tlf: + 47 81 55 99 20
Martin Linges vei 25,N-1367 Snarøya Tlf: + 47 81 55 99 20
Masivet е предназначен за перорална употреба при кучета и трябва да се приема според инструкциите на Вашия ветеринарен лекар.
Masivet is for oral use in dogs and should be given according to your veterinarian’s instructions.
Mastná nebo olejovitá stolice
Fatty or oily stools
Mastná nebo olejovitá stolice
Fatty or oily stools.
Matever 1 000 mg
Matever 1000 mg
Matever 1 000 mg филмирани таблетки Леветирацетам
Matever 1000 mg film-coated tablets Levetiracetam
Matever 100 mg/ml концентрат за инфузионен разтвор
Matever 100 mg/ml concentrate for solution for infusion.
Matever 100 mg/ml концентрат за инфузионен разтвор Леветирацетам
Matever 100 mg/ml concentrate for solution for infusion Levetiracetam
Matever 1000 mg съдържа лактоза
Matever 1000 mg tablets contain lactose.
Matever 1000 mg филмирани таблетки съдържа лактоза.
Matever 1000 mg film coated tablets contain lactose.
Matever 250 mg филмирани таблетки Леветирацетам
Matever 250 mg film-coated tablets Levetiracetam
Matever 250 mg филмираните таблетки са сини, продълговати, двойно изпъкнали.
Matever 250 mg: The film-coated tablets are blue, oblong, biconvex.
Matever 250 mg, 750 mg таблетки съдържа сънсет жълто FCF (Е110)
Matever 250mg, 750 mg tablets contain Sunset Yellow FCF (E110).
Matever 500 mg филмирани таблетки Леветирацетам
Matever 500 mg film-coated tablets Levetiracetam
Matever 750 mg филмирани таблетки EU/1/11/711/015
Matever 750 mg film-coated tablets
Matever 750 mg филмирани таблетки Леветирацетам
Matever 750 mg film-coated tablets Levetiracetam
Matever е „генерично лекарство“.
Matever is a ‘generic medicine’.
Matever концентрат е доказано физически съвместим и химически стабилен при смесването му със следните разтворители, за минимум 24 часа, съхраняван в РVС сакове при контролирана температура от 15-25°С.
Matever concentrate was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15-25 °C.
Matever концентрат е доказано физически съвместим и химически стабилен при смесването му със следните разтворители, за поне 24 часа, съхраняван в РVС сакове при контролирана стайна температура 15-25°С.
Matever concentrate was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15- 25°C.
Matever концентрат за инфузионен разтвор (Matever концентрат) е бистра, безцветна и стерилна течност.
Matever concentrate for solution for infusion (Matever concentrate) is a clear, colorless, sterile liquid.
Matever не е показана при деца и юноши под 16 години за самостоятелно лечение (монотерапия)
Matever is not indicated in children and adolescents below 16 years on it’s own (monotherapy)
Matever не е показана при деца и юноши под 16 години, като самостоятелно лечение (монотерапия).
Matever is not indicated in children and adolescents below 16 years on its own (monotherapy).
Matever не се препоръчва по време на бременност и при жени с детероден потенциал, неползващи контрацепция, освен в случаите на клинична необходимост.
Matever is not recommended during pregnancy and in women of childbearing potential not using contraception unless clinically necessary.
Matever не трябва да се използва по време на бременност освен в случай на категорична необходимост.
Matever should not be used during pregnancy unless clearly necessary.
Matever се прилага за хронично лечение.
Matever is used as a chronic treatment.
Matever1000 mg филмираните таблетки са бели, продълговати двойно изпъкнали.
Matever 1000 mg: The film-coated tablets are white, oblong, biconvex.
Matever500 mg; филмираните таблетки са жълти, продълговати, двойно изпъкнали.
Matever 500 mg; The film-coated tablets are yellow, oblong, biconvex.
Matever750 mg филмираните таблетки са розови, продълговати, двойно изпъкнали.
Matever 750 mg; The film-coated tablets are pink, oblong, biconvex.
Mavacoxib е 4-[5-(4- флуорфенил)-3-(трифлуорметил)-1H-пиразол-1-yl]-бензенсулфонамид.
Mavacoxib is 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide.
Mavacoxib има по-дълъг полуживот на елиминиране при домашни животни.
Mavacoxib possessed a longer elimination half-life in client- owned animals.
Mawdsleys Clinical Services, Unit 22, Quest Park, Wheatley Hall Road, Doncaster, DN2 4LT, Обединено кралство.
Mawdsleys Clinical Services, Unit 22, Quest Park, Wheatley Hall Road, Doncaster, DN2 4LT, United Kingdom.
max дарунавир AUC ↑ 53% дарунавир Cmin ↑ 68% дарунавир Cmax ↑ 39%
max darunavir AUC ↑ 53% darunavir Cmin ↑ 68% darunavir Cmax ↑ 39
Maximal plasmakoncentration (Cmax) och yta under kurvan (AUC) för plasmakoncentration av fluoxetin var ungefär dosproportionerliga mellan 0,75 och 1,5 mg/kg med en större än dosproportionerlig ökning vid 3 mg/kg.
The maximum plasma concentration (Cmax) and area under the plasma concentration time curve (AUC) for fluoxetine were approximately dose proportional between 0.75 and 1.5 mg/kg, with a greater than dose proportional increase at 3 mg/kg.
Maximal plasmakoncentration erhålls efter cirka 2 - 3 timmar.
Maximal plasma concentrations are obtained after approximately 2–3 hours.
Maximalt antal perforationer är 42 för alla injektionsflaskor.
Maximum number of piercings is 42 for all presentations.
Maximalt antal perforationer är 42 för alla presentationer.
Maximum number of piercings is 42 for all presentations.
Maximální plazmatické koncentrace (Cmax) a expozice (AUC) guanfacinu se snížily o 54 %, respektive 70 %.
The peak plasma concentrations (Cmax) and exposure (AUC) of guanfacine decreased by 54% and 70% respectively.
Mayne Pharma (France) SAS
Mayne Pharma (France) SAS.
mať ľahšiu tvorbu podliatín
bruise more easily
Maгнезиев стеарат Полисорбат 80
Magnesium stearate Polysorbate 80
Maкрогол 6000
Film coating:
Maксимална дневна доза: Лечение на до четири епизода на пробивна болка, всеки с не повече от две дози, разделени най-малко през 10 минути.
Maximum daily dose: Treatment of up to four breakthrough pain episodes, each with no more than two doses separated by at least 10 minutes.
Maнитол Mикрокристална целулоза Кросповидон
Mannitol Microcrystalline cellulose Crospovidone
Maнитол Царевично нишесте
Mannitol Maize starch
mBMI промяна от изходната стойност
mBMI change from BL
McDermott Laboratories Limited t/a g erard Laboratories Unit 35/36 Baldoyle Industrial Estate
McDermott Laboratories Limited t/a Gerard Laboratories Unit 35/36 Baldoyle Industrial Estate
McDermott Laboratories Limited t/a Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ирландия
McDermott Laboratories Limited t/a Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland
McDermott Laboratories Limited t/a Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ирланзия
McDermott Laboratories Limited t/a Gerard Laboratories, 35/36 Baldoyle Industrial Estate, Grange Road, Dublin 13, Ireland
McDermott Laboratories Ltd. t/a g erard Laboratories 35/36 Baldoyle Industrial Estate, g range Road Dublin 13
McDermott Laboratories Ltd. t/a Gerard Laboratories 35/36 Baldoyle Industrial Estate, Grange Road Dublin 13
McDermott Laboratories Ltd. t/a Gerard Laboratories 35/36 Baldoyle Industrial Estate,
McDermott Laboratories Ltd. t/a Gerard Laboratories 35/36 Baldoyle Industrial Estate
MCyR е постигнат при 55% от иматиниб-резистентните пациенти и 82% от пациентите с непоносимост към иматиниб.
MCyR was achieved in 55% of imatinib-resistant patients and 82% of imatinib-intolerant patients.
MCyRв
MCyRc
MD 21703-8619, САЩ
MD 21703-8619, USA
MD: целия рисков период.
MD: entire risk period.
Mechanismus účinku guanfacinu u pacientů s ADHD není zcela objasněn.
The mode of action of guanfacine in ADHD is not fully established.
Mechanizmem interakce je
The mechanism of interaction is a
Mechanizmus interakce spočívá
may be necessary.
Mechanizmus interakce spočívá v
The mechanism of interaction is
Mechanizmus interakce spočívá v indukci CYP3A antiepileptiky.
The mechanism of interaction is CYP3A induction by the antiepileptic.
Mechanizmus interakce spočívá v indukci CYP3A4 bosentanem.
The mechanism of interaction is induction of CYP3A4 by bosentan.
Mechanizmus interakce spočívá v indukci CYP3A4 etravirinem.
The mechanism of interaction is CYP3A4 induction by etravirine.
Mechanizmus interakce spočívá v indukci CYP3A4 rifampicinem.
The mechanism of interaction is CYP3A4 induction by rifampicin.
Mechanizmus interakce spočívá v inhibici CYP3A.
The mechanism of interaction is CYP3A inhibition.
Mechanizmus interakce spočívá v inhibici CYP3A4 a P-gp kobicistatem.
The mechanism of interaction is CYP3A4 and P-gp inhibition by cobicistat.
Mechanizmus interakce spočívá v inhibici CYP3A4 a UGT1A1 atazanavirem.
The mechanism of interaction is CYP3A4 and UGT1A1 inhibition by atazanavir.
Mechanizmus interakce spočívá v inhibici CYP3A4 atazanavirem a kobicistatem.
inhibition of CYP3A4 by atazanavir and cobicistat.
Mechanizmus interakce spočívá v inhibici CYP3A4 atazanavirem a kobicistatem.
The mechanism of interaction is CYP3A4 inhibition by atazanavir and cobicistat.
Mechanizmus interakce spočívá v inhibici CYP3A4 atazanavirem, kobicistatem a ketokonazolem nebo itrakonazolem.
The mechanism of interaction is CYP3A4 inhibition by atazanavir, cobicistat and ketoconazole or itraconazole.
Mechanizmus interakce spočívá v inhibici CYP3A4 kobicistatem.
The mechanism of interaction is CYP3A4 inhibition by cobicistat.
Mechanizmus interakce spočívá v inhibici CYP3A4 kobicistatem.
The mechanism of interaction is inhibition of CYP3A4 by
Mechanizmus interakce spočívá v inhibici P-gp atazanavirem a kobicistatem.
The mechanism of interaction is P-gp inhibition by atazanavir and cobicistat.
Mechanizmus interakce spočívá v inhibici UGT1A1 atazanavirem.
The mechanism is UGT1A1
Mechanizmus interakce spočívá v inhibici UGT1A1 atazanavirem.
The mechanism of interaction is inhibition of UGT1A1 by atazanavir.
Mechanizmus tohoto poklesu není znám (viz body 4.2 a 4.4).
The mechanism of this decrease is unknown (see sections 4.2 and 4.4.)
Mechanizmus této interakce spočívá v inhibici CYP3A4 atazanavirem a kobicistatem.
The mechanism of this interaction is CYP3A4 inhibition by atazanavir and cobicistat.
Mechanizmus účinku
Mechanism of action